Vor Biopharma
Develops licensed telitacicept for autoimmune diseases outside Greater China.
$22.65
After-hours close0.00 (0.00%)
At close$22.65(−3.74%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.81 | — | — |
| Aug 2026 | −$0.86 | −$1.16 | −35.4% |
| May 2026 | −$0.75 | −$0.73 | +2.7% |
| Mar 2026 | −$1.14 | $44.50 | +4,003.5% |
| Nov 2025 | −$3.06 | −$3.33 | −8.8% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.81 | — | — | — | — | — |
| Aug 11, 2026 | −$0.86 | −$1.16 | −35.4% | — | — | — |
| May 13, 2026 | −$0.75 | −$0.73 | +2.7% | — | — | — |
| Mar 30, 2026 | −$1.14 | $44.50 | +4,003.5% | — | — | — |
| Nov 13, 2025 | −$3.06 | −$3.33 | −8.8% | — | — | — |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 14, 2025 | ||||||
| Mar 20, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 20, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 23, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 14, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 9, 2021 | ||||||
| May 6, 2021 | ||||||
| Mar 25, 2021 | ||||||
| Dec 18, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||